A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Enzastaurin (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Biomarker; Therapeutic Use
- Acronyms ENGINE
- Sponsors Denovo Biopharma
- 24 Oct 2017 According to a Denovo Biopharma media release, US FDA has granted IND clearance to proceed for this trial and it is recently approved by Food and Drug Administration (CFDA).
- 28 Aug 2017 Status changed from planning to not yet recruiting.
- 20 Feb 2017 New trial record